» Articles » PMID: 33240090

Revisiting Antiarrhythmic Drug Therapy for Atrial Fibrillation: Reviewing Lessons Learned and Redefining Therapeutic Paradigms

Overview
Journal Front Pharmacol
Date 2020 Nov 26
PMID 33240090
Citations 20
Authors
Affiliations
Soon will be listed here.
Abstract

Since the clinical use of digitalis as the first pharmacological therapy for atrial fibrillation (AF) 235 years ago in 1785, antiarrhythmic drug therapy has advanced considerably and become a cornerstone of AF clinical management. Yet, a preventive or curative panacea for sustained AF does not exist despite the rise of AF global prevalence to epidemiological proportions. While multiple elevated risk factors for AF have been established, the natural history and etiology of AF remain incompletely understood. In the present article, the first section selectively highlights some disappointing shortcomings and current efforts in antiarrhythmic drug therapy to uncover reasons why AF is such a clinical challenge. The second section discusses some modern takes on the natural history of AF as a relentless, progressive fibro-inflammatory "atriomyopathy." The final section emphasizes the need to redefine therapeutic strategies on par with new insights of AF pathophysiology.

Citing Articles

Catheter ablation using pulsed-field energy: Advantages and limitations compared with conventional energy.

Kuroki K, Tada H J Arrhythm. 2025; 41(1):e70011.

PMID: 39906095 PMC: 11792576. DOI: 10.1002/joa3.70011.


Exploration of vanoxerine analogues as antibacterial agents.

Kingdon A, Adcock H, Kasimati E, Craven P, van Schaik W, Cox L J Antibiot (Tokyo). 2024; 78(1):54-63.

PMID: 39402358 PMC: 11700842. DOI: 10.1038/s41429-024-00781-9.


Effects of SZV-2649, a new multiple ion channel inhibitor mexiletine analogue.

Mohammed A, Naveed M, Szabados T, Szatmari I, Lorinczi B, Matyus P Sci Rep. 2024; 14(1):23188.

PMID: 39369049 PMC: 11455950. DOI: 10.1038/s41598-024-73576-5.


Cardiac Arrhythmias and Their Management: An In-Depth Review of Current Practices and Emerging Therapies.

Nagpal A, Pundkar A, Singh A, Gadkari C Cureus. 2024; 16(8):e66549.

PMID: 39252710 PMC: 11381938. DOI: 10.7759/cureus.66549.


Long-term amelioration of an early-onset familial atrial fibrillation model with AAV-mediated in vivo gene therapy.

Hu H, Wang L, Li H, Li H, Chen X, Peng W Fundam Res. 2024; 2(6):829-835.

PMID: 38933375 PMC: 11197581. DOI: 10.1016/j.fmre.2022.05.002.


References
1.
Pratt C, Roy D, Torp-Pedersen C, Wyse D, Toft E, Juul-Moller S . Usefulness of vernakalant hydrochloride injection for rapid conversion of atrial fibrillation. Am J Cardiol. 2010; 106(9):1277-83. DOI: 10.1016/j.amjcard.2010.06.054. View

2.
Sieweke J, Pfeffer T, Biber S, Chatterjee S, Weissenborn K, Grosse G . miR-21 and NT-proBNP Correlate with Echocardiographic Parameters of Atrial Dysfunction and Predict Atrial Fibrillation. J Clin Med. 2020; 9(4). PMC: 7230176. DOI: 10.3390/jcm9041118. View

3.
Reiffel J, Camm A, Belardinelli L, Zeng D, Karwatowska-Prokopczuk E, Olmsted A . The HARMONY Trial: Combined Ranolazine and Dronedarone in the Management of Paroxysmal Atrial Fibrillation: Mechanistic and Therapeutic Synergism. Circ Arrhythm Electrophysiol. 2015; 8(5):1048-56. DOI: 10.1161/CIRCEP.115.002856. View

4.
Kusunose K, Zhang Y, Mazgalev T, Van Wagoner D, Thomas J, Popovic Z . Impact of vagal nerve stimulation on left atrial structure and function in a canine high-rate pacing model. Circ Heart Fail. 2014; 7(2):320-6. PMC: 4056587. DOI: 10.1161/CIRCHEARTFAILURE.113.000937. View

5.
Schmidt C, Wiedmann F, Zhou X, Heijman J, Voigt N, Ratte A . Inverse remodelling of K2P3.1 K+ channel expression and action potential duration in left ventricular dysfunction and atrial fibrillation: implications for patient-specific antiarrhythmic drug therapy. Eur Heart J. 2017; 38(22):1764-1774. DOI: 10.1093/eurheartj/ehw559. View